• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Biotech Renaissance Man

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-06-01-2001
Volume 0
Issue 0

The founder of five biotech companies rarely pauses, even to rest. "I can do a lot of work when the rest of my family is sleeping," he reports. "Early in the morning or late at night, there are no phones, so I needn't divert my attention." His affable tone seems contrary to the relentless drive needed to support a lifelong pursuit of excellence, but his achievements speak for themselves.

Articles in this issue
Industry Under Investigation
Covering the Bases
Emotion - The New Brand Integrator
For Love of the Game
Field of Dreams
Workshop: Access Options
Emotion - The New Brand Integrator
Rx-to-OTC: Unwanted Attention
Emotion - Biotech Renaissance Man
Biotech Renaissance Man
Relocation: Coming to America
Biotechnology: German Industry Beefs Up
Stocks: Catching the Market Blues
Gathering Light
Recent Videos
Related Content
Nucala Significantly Reduces Moderate to Severe Exasperations in Chronic Obstructive Pulmonary Disease

Nucala Significantly Reduces Moderate to Severe Exasperations in Chronic Obstructive Pulmonary Disease

Don Tracy, Associate Editor
September 6th 2024
Article

Results from the MATINEE trial found that Nucala led to a statistically significant and clinically meaningful reduction in moderate/severe exacerbations of chronic obstructive pulmonary disease compared to placebo over 104 weeks.

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Miranda Schmalfuhs
September 6th 2024
Podcast

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

FDA Approves Boruzu for Subcutaneous, Intravenous Administration for Multiple Myeloma, Mantle Cell Lymphoma

FDA Approves Boruzu for Subcutaneous, Intravenous Administration for Multiple Myeloma, Mantle Cell Lymphoma

Don Tracy, Associate Editor
September 6th 2024
Article

Boruzu is the first ready-to-use version of bortezomib for subcutaneous and intravenous administration in the treatment of multiple myeloma and mantle cell lymphoma.

Empty Shelves, Urgent Solutions

Empty Shelves, Urgent Solutions

Miranda Schmalfuhs
August 5th 2024
Podcast

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts, alternative solutions to ensure continued access to medications for all Americans, potential long term consequences if these pharmacy closures continue, and more

Pharma Pulse 9/6/24: Gaps and Opportunities in Qualitative Systematic Reviews, Companies Grapple With Expanding Cyber Rules & more

Pharma Pulse 9/6/24: Gaps and Opportunities in Qualitative Systematic Reviews, Companies Grapple With Expanding Cyber Rules & more

Miranda Schmalfuhs
September 6th 2024
Article

The latest news for pharma industry insiders.

Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes

Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes

Don Tracy, Associate Editor
September 5th 2024
Article

Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.